Shenzhen Ionova Life Sciences Co., Ltd.

4 clinical trials · Sponsor

Record	Firm	Date
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations (NCT07610798)	Shenzhen Ionova Life Sciences Co., Ltd.	2026-06-01
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor (NCT07612891)	Shenzhen Ionova Life Sciences Co., Ltd.	2025-07-04
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer (NCT06609005)	Shenzhen Ionova Life Sciences Co., Ltd.	2025-01-23
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (NCT04443088)	Shenzhen Ionova Life Sciences Co., Ltd.	2020-06-26

Every clearance here is in the API, with alerts when new ones post.